Go Pro
→ Elon Musk to Trigger Next AI Wave on November 11th? (From Brownstone Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
$12.51
$17.26
$5.95
▼
$62.75
$1.06B1.041.14 million shs2.38 million shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
0.00%-16.66%-24.04%-34.81%-76.23%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
$12.51
$17.26
$5.95
▼
$62.75
$1.06B1.041.14 million shs2.38 million shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
0.00%-16.66%-24.04%-34.81%-76.23%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
2.41
Hold$24.5796.41% Upside

Current Analyst Ratings Breakdown

Latest MLTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/21/2026
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
8/13/2026
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$45.00 ➝ $50.00
8/7/2026
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/20/2026
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$45.00
7/1/2026
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$24.00 ➝ $29.00
(Data available from 9/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
N/AN/AN/AN/A$4.27 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
-$227.32M-$3.84N/AN/AN/AN/A-82.53%-58.17%11/4/2026 (Estimated)

Latest MLTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/10/2026Q2 2026
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
-$0.9086-$0.84+$0.0686-$0.84N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
0.23
12.56
12.56

Institutional Ownership

CompanyInstitutional Ownership
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
93.85%

Insider Ownership

CompanyInsider Ownership
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
10.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
13085.11 million76.26 millionOptionable

Recent News About These Companies

MLTX stock on track for worst week since last fall as FDA filing date for skin disease drug draws near
September 11 at 6:09 PM  |  msn.comhttps://www.msn.com/en-in/health/diseases-and-conditions/mltx-stock-on-track-for-worst-week-since-last-fall-as-fda-filing-date-for-skin-disease-drug-draws-near/ar-AA2c2W70
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Down 7.7% - Time to Sell?
September 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-moonlake-immunotherapeutics-nasdaq-mltx-shares-down-77-time-to-sell-2026-09-09/
MoonLake Immunotherapeutics: The Bull Case Does Not Require Clinical Supremacy
September 8, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4943841-moonlake-immunotherapeutics-the-bull-case-does-not-require-clinical-supremacy?utm_source=marketbeat.com&utm_medium=referral&feed_item_type=article?source=MarketBeat
MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Consensus Recommendation of "Hold" by Analysts
September 4, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31001976
MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Consensus Rating of "Hold" by Brokerages
September 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-moonlake-immunotherapeutics-nasdaq-mltx-given-consensus-rating-of-hold-by-brokerages-2026-09-04/
MoonLake Immunotherapeutics (MLTX)
August 23, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/quote/MLTX/earnings-calls/
Bank of America Corp DE Has $13.51 Million Stock Holdings in MoonLake Immunotherapeutics $MLTX
August 22, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-has-1351-million-stock-holdings-in-moonlake-immunotherapeutics-mltx-2026-08-22/
HC Wainwright Issues Negative Estimate for MLTX Earnings
August 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/hc-wainwright-issues-negative-estimate-for-mltx-earnings-2026-08-17/
Dimensional Fund Advisors LP Has $490,000 Position in MoonLake Immunotherapeutics $MLTX
August 16, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-dimensional-fund-advisors-lp-has-490000-position-in-moonlake-immunotherapeutics-mltx-2026-08-16/
MoonLake’s psoriatic arthritis drug shows promise in phase 3 trial – retail shrugs off premarket slide, says ‘pipeline is intact’
August 11, 2026  |  msn.comhttps://www.msn.com/en-us/money/general/moonlake-s-psoriatic-arthritis-drug-shows-promise-in-phase-3-trial-retail-shrugs-off-premarket-slide-says-pipeline-is-intact/ar-AA29M2Fr
MoonLake Immunotherapeutics Q2 Loss Narrows, Phase 3 PsA Trial Meets Clinical Goals
August 10, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/moonlake-immunotherapeutics-q2-loss-narrows-130809814.html
MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical ...
August 10, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/moonlake-announces-positive-topline-results-from-the-phase-3-izar-1-trial-of-sonelokimab-in-psoriatic-arthritis-demonstrating-significant-improvements-across-all-clinical-endpoints-and-reports-1036435278
MoonLake’s Psoriatic Arthritis Drug Shows Promise In Late-Stage Study
August 10, 2026  |  benzinga.comhttps://www.benzinga.com/news/health-care/26/08/61084682/moonlakes-psoriatic-arthritis-drug-shows-promise-in-late-stage-study
MoonLake's psoriatic arthritis drug meets key goals in late-stage trial
August 10, 2026  |  reuters.comhttps://www.reuters.com/business/healthcare-pharmaceuticals/moonlakes-psoriatic-arthritis-drug-meets-key-goals-late-stage-trial-2026-08-10/
MoonLake announces positive Phase 3 psoriatic arthritis results
August 10, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/moonlake-announces-positive-phase-3-psoriatic-arthritis-results?utm_source=marketbeat.com&utm_medium=referral
MoonLake reports positive Phase 3 PsA data and $537 million cash
August 10, 2026  |  quiverquant.comQ
MoonLake Immunotherapeutics GAAP EPS of -$0.84
August 10, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4629815-moonlake-immunotherapeutics-gaap-eps-of-0_84?utm_source=marketbeat.com&utm_medium=referral&feed_item_type=news?source=MarketBeat
MLTX stock under pressure as investors await psoriatic arthritis trial data
August 3, 2026  |  msn.comhttps://www.msn.com/en-us/health/other/mltx-stock-under-pressure-as-investors-await-psoriatic-arthritis-trial-data/ar-AA29jWks
Why MoonLake Immunotherapeutics’s (MLTX) Stock Is Down 5.02%
August 3, 2026  |  aaii.comA
Wall Street Analysts See a 73.35% Upside in MOONLAKE IMMUNO (MLTX): Can the Stock Really Move This High?
July 31, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2965735/wall-street-analysts-see-a-73-35-upside-in-moonlake-immuno-mltx-can-the-stock-really-move-this-high?cid=cs-stocknewsapi-ft-tale_of_the_tape|consensus_price_target-2965735
Kristian Reich Sells 1,100 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock
July 30, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-mltx-insider-buying-and-selling-2026-07-30/

New MarketBeat Followers Over Time

Media Sentiment Over Time

MoonLake Immunotherapeutics stock logo

MoonLake Immunotherapeutics NASDAQ:MLTX

$12.51 0.00 (0.00%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$12.52 +0.01 (+0.04%)
As of 06:36 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas